OncoMatch/Clinical Trials/NCT06637007
Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma
Is NCT06637007 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Chidamide Tablets combined with AK112 for sarcoma,soft tissue.
Treatment: Chidamide Tablets combined with AK112 — Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard treatment — first-line
Patients with advanced bone and soft tissue sarcoma who experience disease progression or failure after first-line standard treatment
Cannot have received: histone deacetylase inhibitor (sildenafil)
Patients who have previously used sildenafil or other histone deacetylase inhibitors
Cannot have received: immune checkpoint inhibitor
Previously received treatment with immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
Cannot have received: systemic anti-tumor therapy
Received systemic anti-tumor therapy, including chemotherapy, immunotherapy, and biological therapy (such as tumor vaccines, cytokines, or growth factors that control cancer), within 28 days before starting the research treatment
Cannot have received: Chinese herbal medicine or traditional Chinese patent medicines with anti-tumor indications
Have received Chinese herbal medicine or traditional Chinese patent medicines and simple preparations with anti-tumor indications within 7 days before starting the research treatment
Cannot have received: systemic anti-tumor therapy (mitomycin C)
Planned systemic anti-tumor therapy within 4 weeks prior to enrollment or during the study medication period, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or use of mitomycin C within 6 weeks prior to receiving experimental drug treatment)
Cannot have received: radiation therapy
Expanded field radiation therapy (EF-RT) was performed within 4 weeks prior to enrollment, or limited field radiation therapy was performed within 2 weeks prior to grouping to assess tumor lesions
Cannot have received: major surgery
Received major surgical treatment, open biopsy, or significant traumatic injury within 28 days prior to enrollment
Cannot have received: other anti-tumor drugs (clinical trial participation)
Participated in clinical trials of other anti-tumor drugs within 28 days prior to enrollment
Lab requirements
Blood counts
hemoglobin ≥90g/L; ANC ≥1.5×10^9/L; platelet ≥80×10^9/L
Kidney function
serum creatinine ≤1.5 ULN or creatinine clearance rate ≥60 ml/min
Liver function
total bilirubin ≤1.5 ULN; ALT and AST ≤2.5 ULN (≤5 ULN with liver metastasis)
Cardiac function
LVEF ≥ low limit of normal (50%)
Adequate organ and bone marrow function ... Blood routine examination standard ... Biochemical tests ... Doppler ultrasound evaluation: Left ventricular ejection fraction (LVEF) ≥ Low limit of normal (50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06637007 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior histone deacetylase inhibitor, immune checkpoint inhibitor, systemic anti-tumor therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages